CLLS
Price
$4.84
Change
+$0.01 (+0.21%)
Updated
Dec 24 closing price
Capitalization
485.14M
76 days until earnings call
Intraday BUY SELL Signals
MDGL
Price
$602.82
Change
+$0.61 (+0.10%)
Updated
Dec 24 closing price
Capitalization
13.69B
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLLS vs MDGL

Header iconCLLS vs MDGL Comparison
Open Charts CLLS vs MDGLBanner chart's image
Cellectis SA
Price$4.84
Change+$0.01 (+0.21%)
Volume$51.16K
Capitalization485.14M
Madrigal Pharmaceuticals
Price$602.82
Change+$0.61 (+0.10%)
Volume$103.02K
Capitalization13.69B
CLLS vs MDGL Comparison Chart in %
View a ticker or compare two or three
VS
CLLS vs. MDGL commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a StrongBuy and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (CLLS: $4.84 vs. MDGL: $602.82)
Brand notoriety: CLLS and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLLS: 46% vs. MDGL: 28%
Market capitalization -- CLLS: $485.14M vs. MDGL: $13.69B
CLLS [@Biotechnology] is valued at $485.14M. MDGL’s [@Biotechnology] market capitalization is $13.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLLS’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CLLS’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than CLLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • CLLS’s TA Score: 5 bullish, 4 bearish.
  • MDGL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLLS is a better buy in the short-term than MDGL.

Price Growth

CLLS (@Biotechnology) experienced а +21.91% price change this week, while MDGL (@Biotechnology) price change was +10.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

CLLS is expected to report earnings on Mar 11, 2026.

MDGL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($13.7B) has a higher market cap than CLLS($485M). CLLS YTD gains are higher at: 168.889 vs. MDGL (95.359). CLLS has higher annual earnings (EBITDA): -6.07M vs. MDGL (-270.14M). MDGL has more cash in the bank: 1.11B vs. CLLS (190M). CLLS has less debt than MDGL: CLLS (92.8M) vs MDGL (346M). MDGL has higher revenues than CLLS: MDGL (741M) vs CLLS (75.3M).
CLLSMDGLCLLS / MDGL
Capitalization485M13.7B4%
EBITDA-6.07M-270.14M2%
Gain YTD168.88995.359177%
P/E RatioN/AN/A-
Revenue75.3M741M10%
Total Cash190M1.11B17%
Total Debt92.8M346M27%
FUNDAMENTALS RATINGS
CLLS vs MDGL: Fundamental Ratings
CLLS
MDGL
OUTLOOK RATING
1..100
1867
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
10015
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLLS's Valuation (35) in the Biotechnology industry is in the same range as MDGL (65) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for CLLS (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CLLS’s over the last 12 months.

CLLS's SMR Rating (96) in the Biotechnology industry is in the same range as MDGL (97) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

CLLS's Price Growth Rating (35) in the Biotechnology industry is in the same range as MDGL (37) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

CLLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLLSMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CLLS
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AHGCX5.920.01
+0.17%
American Century Heritage C
LICYX18.22N/A
N/A
Lord Abbett International Equity I
FGETX24.49N/A
N/A
Fidelity Advisor Glbl Capital Apprec M
CMIRX9.53N/A
N/A
Conestoga Discovery Institutional
GLPRX33.23-0.05
-0.15%
Goldman Sachs MLP Energy Infras R

CLLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been closely correlated with CMVLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLLS jumps, then CMVLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
+0.21%
CMVLF - CLLS
82%
Closely correlated
N/A
SLN - CLLS
43%
Loosely correlated
-2.07%
MDGL - CLLS
40%
Loosely correlated
+0.10%
PMVP - CLLS
38%
Loosely correlated
+0.41%
AXON - CLLS
36%
Loosely correlated
+0.02%
More